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S224 Oral Presentations(36%) were associated with less OM (HR 0.78; P 5 .04) and NRM
(HR 0.70; P 5 .02).
For the first time in HSCT, this study demonstrates the impact of
3DL1 allotypes inHSCT, where combinations of 3DL1-high and their
high affinity Bw4 alleles in the donor are associated with higher relapse
andOMin patients. Conversely, donor 3DS1 is associatedwith lessOM
and NRM. These data offer insights to differential controls of NK bi-
ology inHSCT and support not only KIR genotyping but KIR allotyp-
ing in order to select donors with the best KIR-HLA combinations to
maximize leukemic control while minimizing unwanted toxicities.57
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Allogeneic hematopoietic cell transplant (HCT) is a widely used
therapy for hematologic malignancy. It is important to give the op-
tion of HCT to patients without an HLA-matched donor; this is
most acute for ethnic minorities. Haploidentical HCT may offer
the best or only chance for cure but often fails due to persistant ma-
lignancy or fatal toxicity. It is important to improve disease control
without increased toxicity of the regimen. We have shown that
CD45 radioimmunotherapy (RIT) delivers radiation to leukemic
sites, sparing normal organs. We hypothesize haploidentical HCT
may be enhanced via CD45RIT bymaximizing delivery to target tis-
sue with minimal toxicity by reducing total-body irradiation (TBI)
and chemotherapy.We performed studies to find the maximal inten-
sity of anti-leukemic RIT combined with haploidentical HCT while
preserving graft-versus-leukemia effects. We established an HCT
regimen in B6SJLF1/J mice (H-2Db haplotype) conditioned with
fludarabine (FLU, days -6 to -2), followed by TBI (250, 500, 750
cGy; day -1). Mice received 15 million donor (CB6F1/J, H-2Dd)
BM cells (day 0), then cyclophosphamide (CY) for graft-versus-
host disease (GvHD) prophylaxis (day +2). Chimerism was TBI
dose-dependent; mice receiving $500 cGy were fully chimeric 4
weeks post-HCT, persisting $8 months. We then treated
B6SJLF1/J mice with or without FLU and 200-400 mCi of 90Y-la-
beled anti-murine CD45 Ab (30F11, day -3), followed by 15 million
donor BM cells (day 0) and CY (day +2). All mice receiving 200 or
300 mCi 90Y-CD45Ab survived 30 days after HCTwith no evidence
of toxicity or GvHD. Four of 10 mice receiving 400 mCi 90Y-CD45
Ab died by day 25 due to toxicity. At day 25 blood was taken to detect
chimerism via flow cytometry. Three of 5 mice that received 200 mCi
90Y-CD45 Ab and FLU showed chimerism with 23-77% CD8+ T-
cells expressing H-2Dd. Four of 5 (80%) mice receiving 300 mCi
90Y-30F11 and 2/3 (67%) receiving 400 mCi 90Y-30F11, in the pres-
ence of FLU, were chimeric with 22-89% and 25-64%CD8+ donor
cells, respectively. Mice receiving 200, 300, or 400 mCi 90Y-CD45
Ab without FLU were chimeric with 10-71% donor cells in 4/5
(80%), 2/5 (40%) and 1/4 (25%) mice, respectively. These data sug-
gest anti-CD45 RIT may be a well-tolerated regimen allowing en-
graftment of haploidentical marrow without TBI and
chemotherapy. Current studies testing pretargeted RIT may im-
prove targeting of malignant CD45+ cells with reduced TBI and
FLU, and increased therapeutic index.IMMUNE RECONSTITUTION58
EARLY POST-TRANSPLANT WHOLE TUMOR CELL-BASED VACCINATION
ALTERS THE KINETICS OF T CELL RECONSTITUTION
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cer Institute, Boston, MA; 2Adaptive TCR Technologies, Seattle, WAWhole tumor cell-based vaccines administered in the early post-
transplant (HSCT) setting are a promising approach to enhance
graft-versus-leukemia responses. Our previous studies described
the detection of increasedCD8+T cells with specificity for autologous
chronic lymphocytic leukemia (CLL) cells in association with attain-
ment of molecular remission within 6 months post-HSCT that devel-
oped following early-post transplant tumor vaccination (initiating at
day 30-45). The series of vaccines were comprised of irradiated autol-
ogous tumor admixed with irradiated GM-CSF secreting bystander
cells. It is unknown how this early post-transplant intervention shapes
the reconstituting donor T cell repertoire. One approach to character-
ize this is through examining the kinetics of recovery of T cell receptor
(TCR) beta-chain diversity using recently developed methodologies
that apply deep sequencing techniques for the analysis of the highly
variable complementarity-determining region 3 (CDR3) of the
TCR. We therefore isolated na€ıve and memory T cells from the
CD8 andCD4 compartments from 12 patients (6with vaccine, 6 with-
out) at time points informative for thymic-independent (early; 4month
post-transplant) and thymic-dependent (late; 1 year post-transplant) T
cell immune recovery. The isolated cell subsets directly underwent
PCR amplification of the CDR3 region to generate a template library
that was then sequenced using the IlluminaGA2 system.We obtained
a median of 24,191 productive reads per sample (range 0-8,900,000).
To evaluate theTCRdiversity, we calculated the normalized probabil-
ity distribution (‘entropy’) of eachT cell compartment.Overall, we ob-
served that the 6 vaccinated subjects demonstrated a higher
normalized entropy at day 120 (p 5 0.008) and more unique CDR3
sequences (one-tailed t-test with unequal variance: p 5 0.03) com-
pared to non-vaccinated subjects. In particular, CD8+ memory and
na€ıve cells exhibited greater TCR diversity at days 120 and 365 in vac-
cinated than in non-vaccinated individuals. These results suggest that
early post-transplant vaccination exerts an active role in shaping T cell
reconstitution.Ongoing analyses focus on the integration ofTCR rep-
ertoire data with the assessment of minimal residue disease, immuno-
phenotyping and TCR excision circle (TREC) analysis. The results
gained within this study provide us with critical information as we for-
mulate the next generation of post-transplant cancer vaccines.59
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT/Cy) PRESERVES EFFEC-
TOR (Teff) AND REGULATORY (Treg) T CELLS DURING EARLY IMMUNE
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Emerging clinical data suggest that high-dose PT/Cy is effective
in preventing both acute and chronic GVHD, but the mechanisms
accounting for these effects have not been fully characterized. We
hypothesized that PT/Cy prevents acuteGVHD (aGVHD) by selec-
tively depleting highly proliferative alloreactive T cells stimulated
early after transplant, while sparing Tregs. We analyzed the pheno-
typic reconstitution of CD4+ T cells at days 30 and 60 after trans-
plant in a cohort of 47 consecutive patients (median age 50) that
received HLA-matched allografts and PT/Cy as sole GVHD pro-
phylaxis. CD4+Foxp3+ T cells were partitioned into three pheno-
typic fractions (Fr) with distinct functions: CD45RA+Foxp3+lo (Fr
I), CD45RA-Foxp3+hi (Fr II), and CD45RA-Foxp3+lo (Fr III), repre-
senting naive Tregs, activated Tregs, and non-suppressive, cytokine-
secreting Teff, respectively. In both patients with and without
aGHVD, Teff (Fr III) percentages were increased compared with
healthy donors (p 5 0.004), and were higher in patients with
aGVHD compared with patients without aGVHD (p5 0.0003). In-
terestingly, patients with aGVHD also had higher percentages of ac-
tivated Tregs (Fr II, p 5 0.01) compared with patients without
aGVHD. These relative increases in Fr II and III persisted despite
steroid-induced lymphopenia. The relative expansion of Tregs in pa-
tients with aGVHD was an unexpected finding, since aGVHD is as-
sociated with lower Tregs in studies using traditional GVHD
prophylaxis incorporating calcineurin inhibitors (CNIs). To assess
differential effects of PT/Cy and CNI on T cell reconstitution in
